Have a question?
Please get in touch with our team in case of any queries
THE GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET SIZE WAS VALUED AT USD 3.59 BILLION IN 2022 AND IS EXPECTED TO REACH USD 7.16 BILLION BY 2028, GROWING AT A CAGR OF 12.19%.
The Global Alzheimer's Disease Therapeutics Market Share, Size, & Trends Analysis Report by
- Drug Class: ACE Inhibitors, NMDA Inhibitors, and Other Drug class
- Gender Type: Men and Women
- Age Group: 65-74 years, 75-84 years, and 85 years & Above
- Severity Type: Mild, Moderate, and Severe
- Geography: North America (United States), APAC (China, Japan), and Europe (France, Germany, Italy, Spain, and the UK)
This report includes market data points, ranging from trend
analyses to market estimates & forecasts that you can customize
ALZHEIMER'S DISEASE THERAPEUTICS MARKET REPORT SCOPE
| REPORT ATTRIBUTE | DETAILS |
|---|---|
| Market Size (2028) | USD 7.16 Billion |
| Market Size (2022) | USD 3.59 Billion |
| CAGR (2022-2028) | 12.19% |
| HISTORIC YEAR | 2019-2021 |
| BASE YEAR | 2022 |
| FORECAST YEAR | 2023-2028 |
| SEGMENTS BY | Drug Class, Gender Type, Age Group, Severity Type, and Geography |
| COUNTRIES COVERED | United States, France, Germany, Italy, UK, Spain, China, and Japan |
| KEY PLAYERS | Novartis AG, AbbVie, Biogen, Johnson & Johnson (J&J), Eisai, Green Valley Pharmaceuticals, UCB SA (UCB), KeifeRx, Eli Lilly And Co, BioVie Inc, and NeuroKine Therapeutics |
The global Alzheimer's disease therapeutics market was valued at USD 3.59 billion in 2022 and is expected to reach USD 7.16 billion by 2028, growing at a CAGR of 12.19% from 2022-2028. With the growing prevalence of Alzheimer's worldwide, government and non-government entities are investing heavily in developing therapeutics for the disease, which may augment the market's growth. R&D investments are further expected to propel the Alzheimer's disease therapeutics market growth.
According to Arizton's estimates, the prevalence of Alzheimer's disease was high in China, followed by U.S. and Japan in 2021. In the 8MM, the total prevalent cases increased from 29,460,996 in 2021 to 36,009,144 cases in 2028. The increasing prevalence of Alzheimer's disease is driving the growth of the global Alzheimer's disease therapeutics market. According to the estimates, approximately 900,000 new patients are diagnosed annually in the US alone.
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by memory loss, cognitive impairment, and functional decline. During the early stages of the disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation, either by a home care professional or a family member. With rapidly increasing worldwide prevalence, the international medical community has identified Alzheimer's disease as a major global health threat. Significant efforts have been made to develop a new treatment, as current pharmacologic management is known only temporarily to improve symptoms. Without therapies that effectively stop or reverse the course of the disease, a large area of opportunity exists for developing an effective pharmacologic approach in the global Alzheimer's disease therapeutics market.
The most significant known risk factor is increasing age; most people with Alzheimer's are 65 and older. Alzheimer's disease is considered younger-onset Alzheimer's if it affects a person under 65. Younger-onset can also be referred to as early-onset Alzheimer's. Further, Alzheimer's disease is the most common type of dementia and affected approximately 5.8 million people in the United States in 2020, and the prevalence is expected to double by 2050. According to estimates, approximately 35 million people are affected with Alzheimer's disease globally. In Europe alone, as of 2018, 9.7 million people have Alzheimer's disease and other forms of dementia. By 2030, the number of patients will rise to 14 million. According to estimates, Japan has the highest total prevalence of AD, with 23.88% in women and 11.93% in men, with the total prevalent cases in those 60 years and older forecast to increase from 4.2 million in 2022 to 5.1 million in 2028, at an annual growth rate of 3.5%. Such a growing number of Alzheimer's disease gives significant growth opportunities for the Alzheimer's disease therapeutics market.
Alzheimer's Disease Diagnosis
Several laboratory tests can diagnose Alzheimer's disease to assess memory impairment and other thinking skills, judge functional abilities, and identify behavior changes. The brain-imaging technologies most often used are Magnetic resonance imaging (MRI), Computerized tomography (CT), and Positron emission tomography (PET).
Alzheimer's Disease Treatment
The current competitive landscape in AD consists only of symptomatic treatments, of which there are currently seven approved medications: three ChEIs (donepezil, rivastigmine, and galantamine), one NMDA-R antagonist (memantine), one combination therapy (memantine/donepezil), and two Aβ A4 protein inhibitor (aducanumab and sodium oligomannate). In the global Alzheimer's disease therapeutics market, cholinesterase inhibitors are the major drugs available for Alzheimer's because the enzyme cholinesterase is a significant therapeutic target for Alzheimer's. Improvements to the approved therapies, such as easier routes of administration and reduced dosing frequencies, along with the developments expected to occur within the next decade, could significantly affect how the disease is managed. Earlier disease detection may render the currently available therapies more useful, but until disease-modifying agents are introduced, the landscape will not change significantly.
ALZHEIMER'S DISEASE: CLINICAL TRIALS SCENARIO
The Alzheimer's disease therapeutics market portfolio contains a total of 151+ assets in various development phases. Most industry-sponsored drugs in active clinical development for Alzheimer's Disease are in the Phase II stage.
The clinical trial portfolio contains 139+ trials in various development phases. Most industry-sponsored drugs in active clinical development for Alzheimer's Disease are in the Phase II stage. The global pharmaceutical industry is steadily developing new drugs for Alzheimer's Disease, a Central Nervous System disorder. Moreover, North America boasts the highest number of ongoing clinical trials involving Alzheimer's Disease. Asia-Pacific and Europe are the other prominent regions involved in Alzheimer's Disease-related drug trials. Further, Eli Lilly and Company is the leading ongoing Alzheimer's Disease-related clinical trials sponsor in the Alzheimer's disease therapeutics market. Eisai Co Ltd, Roche Ltd, Cognition Therapeutics Inc, and Cassava Sciences Inc are a few other notable sponsors involving Alzheimer's Disease.
MARKET TRENDS & DRIVERS
Launch of New Therapies
The USFDA approved biological drug candidates such as Aducanumab (Aduhelm) in 2021 for treating early Alzheimer's Disease. With Aduhelm being the biologic approved for Alzheimer's disease in 2021, there is a demand for biological therapies with novel MOAs, and many new classes of therapies are looking to enter the Alzheimer's disease therapeutics market over the next few years. The biologics such as amyloid beta inhibitors are making inroads into the Alzheimer's disease market owing to better clinical profiles and convenient patient dosing. Launching approved small molecules, and further uptake in biological therapies will lead to significant growth in the Alzheimer's Disease therapeutics market.
Increasing Prevalence of Alzheimer's Disease
The Alzheimer's disease therapeutics market has been witnessing considerable growth, which is attributed to the increasing prevalence of Alzheimer's Disease worldwide. According to the estimates, the prevalence of Alzheimer's Disease patients was 6.5 million in the United States in 2022.
High Investment in R&D Activities
Major players in the Alzheimer's disease therapeutics market are developing novel products and spending significantly on research and development, along with major acquisitions and collaborations to achieve a competitive edge over their counterparts. High investments in R&D capabilities and infrastructure by the industry and governments are anticipated to create lucrative opportunities in the market.
SEGMENTATION ANALYSIS
- Drug Class: The ACE inhibitors are expected to account for a significant share of the global Alzheimer's disease therapeutics market by drug class. However, the other class of drugs is expected to be the fastest-growing segment during the forecast period. Recently approved biologic such as Aducanumab (Aduhelm) is expected to drive the global Alzheimer's disease therapeutics market during the forecast period.
- Gender Type: Among the gender type, women were expected to account for a significant share of the global Alzheimer's disease therapeutics market. The majority of the share is due to women's longer life expectancy.
- Age Group: The global Alzheimer's disease therapeutics market by age group people is expected to be dominated by the 85 years & above age group. However, people 65 years & above are expected to be the fastest-growing segment during the study period.
- Severity Type: Among the severity type, People with mild form are expected to account for a significant share of the global Alzheimer's Disease therapeutics market. In 2021, the incidence of Alzheimer's disease was 229,385 in the U.S., projected to grow significantly during the forecast period. However, people with moderate form are expected to be the fastest-growing segment during the forecast period.
GEOGRAPHICAL ANALYSIS
The U.S. dominates the global Alzheimer's disease therapeutics market by geography due to the rise in healthcare affordability in the U.S., the rise in knowledge and awareness amongst the people, and technological advancement in this region. However, China is expected to grow at a faster rate with a high CAGR in the global Alzheimer's disease therapeutics market due to the geriatric population's rise, awareness about disease management, and rising healthcare expenditure in the APAC region.
COMPETITIVE LANDSCAPE
The current competitive landscape in AD consists only of symptomatic treatments, of which there are currently seven approved medications. The global Alzheimer's disease therapeutics market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating Alzheimer's Disease. The U.S. Food and Drug Administration (FDA) approved the amyloid beta antibody Adehulm (Adecanumab) for treating Alzheimer's Disease in 2021. This marked the arrival of biologics in this treatment landscape. Although generic products continue to capture significant Alzheimer's disease therapeutics market share, the arrival of biologics and other targeted therapies indicates a paradigm shift in this therapeutic space through the forecast period.
The global Alzheimer's disease therapeutics market contains 151+ assets in various development phases. The emerging therapeutics being developed for Alzheimer's Disease include Lecanemab, Nilotinib, Remternetug, NE-3107, Bepranemab, Vafidemstat, Seltorexant, and many others. Launching these novel emerging drugs will shift the Alzheimer's Disease therapeutics paradigm shortly. With more than 151 molecules in various stages of development, it is expected that new vendors are likely to enter the market with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating Alzheimer's Disease.
Companies such as Eisai Co., Ltd., Novartis, Biogen, AbbVie, Janssen Pharmaceuticals, and Shanghai Green Valley Pharmaceuticals are the major players in the global Alzheimer's disease therapeutics market. These players adopt organic and inorganic growth strategies to strengthen their product portfolio. These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global Alzheimer's disease therapeutics market. The other prominent emerging players operating in the global Alzheimer's disease market include KeifeRx LLC, BioVie Inc, Eli Lilly and Company, UCB SA, Oryzon Genomics, Denali Therapeutics, and many others.
Key Milestones in The Alzheimer's Disease Therapeutics Market:
- In April 2022, Biogen Announced that the European Medicines Agency (EMA) had withdrawn its Marketing Authorization Application (MAA) for aducanumab to treat the early stages of Alzheimer's disease due to a lack of sufficient data.
- In March 2022, Corium, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved Adlarity (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of Alzheimer's Disease.
- In June 2021, Biogen Announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Aduhelm (aducanumab-avwa) to treat early Alzheimer's disease. The approval is based on two Phase 3 clinical trials—EMERGE (Study 1) and ENGAGE (Study 2)—in patients with early stages of Alzheimer's disease (mild cognitive impairment and mild dementia) with confirmed presence of amyloid pathology.
REPORT COVERS
- Detailed overview of Alzheimer's Disease, including disease definition, classification, diagnosis, and treatment pattern
- Overview of the global trends of Alzheimer's Disease in the eight major markets (8MM)
- Historical, current, and projected patient pool of Alzheimer's Disease in the eight major markets (8MM) for the 2019 – 2028 period
- Gender type, Drug Class, Age group, Severity type, and Geography type segmentations of Alzheimer's Disease in the eight major markets (8MM)
- Historical, current, and projected market size of Alzheimer's Disease in the eight major markets (8MM) for the 2019 – 2028 period
- In-depth analysis of the market segments, which includes products, treatment, and competitor analysis
- Market share of the market players, company profiles, product specifications, and competitive landscape
- Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
- Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities.
- Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Alzheimer's Disease across the complete product development cycle, including all clinical and non-clinical stages
- Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for Alzheimer's Disease across all clinical stages
- Coverage of dormant and discontinued pipeline projects along with the reasons across Alzheimer's Disease
- Coverage of major milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the Alzheimer's Disease space.
Frequently Asked Questions
How big is the Alzheimer's disease therapeutics market?
What is the growth rate of the global Alzheimer's disease therapeutics market?
What are some significant trends in the Alzheimer's disease therapeutics market?
Who are the leading vendors operating in the global Alzheimer's disease therapeutics market?
Which region holds the most extensive global Alzheimer's disease therapeutics market share?
The Alzheimer's disease therapeutics market is expected to grow at a CAGR of approximately 12.19% from 2022 to 2028.
The following factors are likely to contribute to the growth of the Alzheimer's disease therapeutics market during the forecast period:
- Anticipated Launch of Emerging Drugs
- Increasing Prevalence of Alzheimer's Disease
- New Biomarkers for Diagnosis
Base Year: 2022
Forecast Year: 2023-2028
The report considers the present scenario of the Alzheimer's disease therapeutics market and its market dynamics for 2023−2028. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.
Key Vendors
- Novartis AG
- Company Overview
- Product Offerings
- AbbVie Inc (AbbVie)
- Biogen Inc (Biogen)
- Johnson & Johnson (J&J)
- Eisai Co Ltd (Eisai)
- Green Valley Pharmaceuticals
- UCB SA (UCB)
- KeifeRx
- Eli Lilly and Co (Lilly)
- BioVie Inc
- NeuroKine Therapeutics (NKT), LLC
Other Prominent Vendors
- Vaccinex, Inc.
- Company Overview
- Product Offerings
- Alzinova AB
- Asceneuron SA
- Biohaven
- Denali
- Alzamend
Segmentation By Drug Class
- ACE Inhibitors
- NMDA Inhibitors
- Other Drug class
Segmentation By Gender Type
- Men
- Women
Segmentation By Age Group
- 65-74 years
- 75-84 years
- 85 years & Above
Segmentation By Severity Type
- Mild
- Moderate
- Severe
Segmentation By Geography
- North America
- US
- APAC
- China
- Japan
- Europe
- France
- Germany
- UK
- Italy
- Spain
List of Exhibits
- Exhibit 1: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN 8 MAJOR MARKETS (2019 – 2028)
- Exhibit 2: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN 8 MAJOR MARKETS (2019 – 2021)
- Exhibit 3: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN 8 MAJOR MARKETS (2022 – 2028)
- Exhibit 4: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN 8 MAJOR MARKETS (2019 – 2028)
- Exhibit 5: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN 8 MAJOR MARKETS (2019 – 2028)
- Exhibit 6: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN 8 MAJOR MARKETS (2019 – 2028)
- Exhibit 7: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN 8 MAJOR MARKETS (2019 – 2028)
- Exhibit 8: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN 8 MAJOR MARKETS (2019 – 2028)
- Exhibit 9: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN 8 MAJOR MARKETS (2019 – 2028)
- Exhibit 10: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN US (2019 – 2028)
- Exhibit 11: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN US (2019 – 2021)
- Exhibit 12: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN US (2022 – 2028)
- Exhibit 13: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN US (2019 – 2028)
- Exhibit 14: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN US (2019 – 2028)
- Exhibit 15: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN US (2019 – 2028)
- Exhibit 16: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN US (2019 – 2028)
- Exhibit 17: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN US (2019 – 2028)
- Exhibit 18: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN US (2019 – 2028)
- Exhibit 19: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN CHINA (2019 – 2028)
- Exhibit 20: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN CHINA (2019 – 2021)
- Exhibit 21: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN CHINA (2022 – 2028)
- Exhibit 22: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN CHINA (2019 – 2028)
- Exhibit 23: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN CHINA (2019 – 2028)
- Exhibit 24: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN CHINA (2019 – 2028)
- Exhibit 25: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN CHINA (2019 – 2028)
- Exhibit 26: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN CHINA (2019 – 2028)
- Exhibit 27: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN CHINA (2019 – 2028)
- Exhibit 28: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN JAPAN (2019 – 2028)
- Exhibit 29: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN JAPAN (2019 – 2021)
- Exhibit 30: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN JAPAN (2022 – 2028)
- Exhibit 31: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN JAPAN (2019 – 2028)
- Exhibit 32: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN JAPAN (2019 – 2028)
- Exhibit 33: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN JAPAN (2019 – 2028)
- Exhibit 34: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN JAPAN (2019 – 2028)
- Exhibit 35: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN JAPAN (2019 – 2028)
- Exhibit 36: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN JAPAN (2019 – 2028)
- Exhibit 37: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN GERMANY (2019 – 2028)
- Exhibit 38: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN GERMANY (2019 – 2021)
- Exhibit 39: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN GERMANY (2022 – 2028)
- Exhibit 40: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN GERMANY (2019 – 2028)
- Exhibit 41: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN GERMANY (2019 – 2028)
- Exhibit 42: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN GERMANY (2019 – 2028)
- Exhibit 43: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN GERMANY (2019 – 2028)
- Exhibit 44: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN GERMANY (2019 – 2028)
- Exhibit 45: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN GERMANY (2019 – 2028)
- Exhibit 46: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN UK (2019 – 2028)
- Exhibit 47: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN UK (2019 – 2021)
- Exhibit 48: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN UK (2022 – 2028)
- Exhibit 49: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN UK (2019 – 2028)
- Exhibit 50: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN UK (2019 – 2028)
- Exhibit 51: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN UK (2019 – 2028)
- Exhibit 52: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN UK (2019 – 2028)
- Exhibit 53: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN UK (2019 – 2028)
- Exhibit 54: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN UK (2019 – 2028)
- Exhibit 55: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN FRANCE (2019 – 2028)
- Exhibit 56: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN FRANCE (2019 – 2021)
- Exhibit 57: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN FRANCE (2022 – 2028)
- Exhibit 58: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN FRANCE (2019 – 2028)
- Exhibit 59: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN FRANCE (2019 – 2028)
- Exhibit 60: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN FRANCE (2019 – 2028)
- Exhibit 61: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN FRANCE (2019 – 2028)
- Exhibit 62: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN FRANCE (2019 – 2028)
- Exhibit 63: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN FRANCE (2019 – 2028)
- Exhibit 64: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN ITALY (2019 – 2028)
- Exhibit 65: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN ITALY (2019 – 2021)
- Exhibit 66: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN ITALY (2022 – 2028)
- Exhibit 67: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN ITALY (2019 – 2028)
- Exhibit 68: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN ITALY (2019 – 2028)
- Exhibit 69: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN ITALY (2019 – 2028)
- Exhibit 70: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN ITALY (2019 – 2028)
- Exhibit 71: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN ITALY (2019 – 2028)
- Exhibit 72: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN ITALY (2019 – 2028)
- Exhibit 73: HISTORIC & PROJECTED VOLUME OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN SPAIN (2019 – 2028)
- Exhibit 74: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN SPAIN (2019 – 2021)
- Exhibit 75: COMPARATIVE ANALYSIS OF INCIDENCE & PREVALENCE OF ALZHEIMER’S DISEASE IN SPAIN (2022 – 2028)
- Exhibit 76: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN SPAIN (2019 – 2028)
- Exhibit 77: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN SPAIN (2019 – 2028)
- Exhibit 78: HISTORIC & PROJECTED VOLUME OF INCIDENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN SPAIN (2019 – 2028)
- Exhibit 79: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY SEVERITY TYPE IN SPAIN (2019 – 2028)
- Exhibit 80: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY AGE GROUP IN SPAIN (2019 – 2028)
- Exhibit 81: HISTORIC & PROJECTED VOLUME OF PREVALENCE OF ALZHEIMER’S DISEASE BY GENDER TYPE IN SPAIN (2019 – 2028)
- Exhibit 82: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN 8 MAJOR MARKETS (2019 – 2028)
- Exhibit 83: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN 8 MAJOR MARKETS (2019 – 2021)
- Exhibit 84: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN 8 MAJOR MARKETS (2022 – 2028)
- Exhibit 85: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN 8 MAJOR MARKETS (2022 – 2028)
- Exhibit 86: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN 8 MAJOR MARKETS (2022 – 2028)
- Exhibit 87: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY SEVERITY IN 8 MAJOR MARKETS (2022 – 2028)
- Exhibit 88: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN US (2022 – 2028)
- Exhibit 89: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN US (2019 – 2021)
- Exhibit 90: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN US (2022 – 2028)
- Exhibit 91: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN US (2022 – 2028)
- Exhibit 92: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN US (2022 – 2028)
- Exhibit 93: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY SEVERITY IN US (2022 – 2028)
- Exhibit 94: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN CHINA (2022 – 2028)
- Exhibit 95: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN CHINA (2019 – 2021)
- Exhibit 96: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN CHINA (2022 – 2028)
- Exhibit 97: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN CHINA (2022 – 2028)
- Exhibit 98: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN CHINA (2022 – 2028)
- Exhibit 99: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY SEVERITY IN CHINA (2022 – 2028)
- Exhibit 100: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN GERMANY (2022 – 2028)
- Exhibit 101: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN GERMANY (2019 – 2021)
- Exhibit 102: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN GERMANY (2022 – 2028)
- Exhibit 103: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN GERMANY (2022 – 2028)
- Exhibit 104: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN GERMANY (2022 – 2028)
- Exhibit 105: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY SEVERITY TYPE IN GERMANY (2022 – 2028)
- Exhibit 106: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN JAPAN (2022 – 2028)
- Exhibit 107: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN JAPAN (2019 – 2021)
- Exhibit 108: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN JAPAN (2022 – 2028)
- Exhibit 109: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN JAPAN (2022 – 2028)
- Exhibit 110: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN JAPAN (2022 – 2028)
- Exhibit 111: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY SEVERITY TYPE IN JAPAN (2022 – 2028)
- Exhibit 112: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN FRANCE (2022 – 2028)
- Exhibit 113: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN FRANCE (2019 – 2021)
- Exhibit 114: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN FRANCE (2022 – 2028)
- Exhibit 115: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN FRANCE (2022 – 2028)
- Exhibit 116: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN FRANCE (2022 – 2028)
- Exhibit 117: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY SEVERITY TYPE IN FRANCE (2022 – 2028)
- Exhibit 118: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN ITALY (2022 – 2028)
- Exhibit 119: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN ITALY (2019 – 2021)
- Exhibit 120: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN ITALY (2022 – 2028)
- Exhibit 121: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN ITALY (2022 – 2028)
- Exhibit 122: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN ITALY (2022 – 2028)
- Exhibit 123: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY SEVERITY IN ITALY (2022 – 2028)
- Exhibit 124: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN UK (2022 – 2028)
- Exhibit 125: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN UK (2019 – 2021)
- Exhibit 126: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN UK (2022 – 2028)
- Exhibit 127: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN UK (2022 – 2028)
- Exhibit 128: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN UK (2022 – 2028)
- Exhibit 129: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY SEVERITY TYPE IN UK (2022 – 2028)
- Exhibit 130: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN SPAIN (2022 – 2028)
- Exhibit 131: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET SNAPSHOT IN SPAIN (2019 – 2021)
- Exhibit 132: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY AGE GROUP IN SPAIN (2022 – 2028)
- Exhibit 133: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY GENDER TYPE IN SPAIN (2022 – 2028)
- Exhibit 134: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY DRUG CLASS IN SPAIN (2022 – 2028)
- Exhibit 135: HISTORIC & PROJECTED REVENUE OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET BY SEVERITY TYPE IN SPAIN (2022 – 2028)
- Exhibit 136: PIPELINE DRUGS OVERVIEW IN ALZHEIMER’S DISEASE THERAPEUTICS MARKET
- Exhibit 137: ALZHEIMER’S DISEASE PIPELINE DRUGS OVERVIEW BY DISEASE TYPE
- Exhibit 138: ALZHEIMER’S DISEASE PIPELINE DRUGS OVERVIEW BY DEVELOPMENT PHASE
- Exhibit 139: ALZHEIMER’S DISEASE PIPELINE DRUGS OVERVIEW BY ROUTE OF ADMINISTRATION
- Exhibit 140: ALZHEIMER’S DISEASE PIPELINE DRUGS OVERVIEW BY MECHANISM OF ACTION
- Exhibit 141: ALZHEIMER’S DISEASE PIPELINE DRUGS OVERVIEW BY MOLECULE TYPE
- Exhibit 142: ALZHEIMER’S DISEASE PIPELINE DRUGS OVERVIEW BY GEOGRAPHY TYPE
- Exhibit 143: ALZHEIMER’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT
- Exhibit 144: ALZHEIMER’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY RECRUITMENT STATUS
- Exhibit 145: ALZHEIMER’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY PRODUCT TYPE
- Exhibit 146: ALZHEIMER’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY ROUTE OF ADMINISTRATION
- Exhibit 146: ALZHEIMER’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY MOLECULE TYPE
- Exhibit 147: ALZHEIMER’S DISEASE CLINICAL TRIAL ANALYSIS SNAPSHOT BY GEOGRAPHY TYPE
- Exhibit 148: COMPETITIVE ASSESSMENT OF ALZHEIMER’S DISEASE THERAPEUTICS MARKET
Tables
- Table 1: KEY MARKET DRIVERS IN ALZHEIMER’S DISEASE THERAPEUTICS MARKET
- Table 2: KEY MARKET CONSTRAINTS IN ALZHEIMER’S DISEASE THERAPEUTICS MARKET
- Table 3: KEY MARKET TRENDS IN ALZHEIMER’S DISEASE THERAPEUTICS MARKET
- Table 4: KEY TENTATIVE TIMELINE APPROVALS OF PIPELINE DRUGS IN ALZHEIMER’S DISEASE
- Table 5: KEY REGULATORY DESIGNATIONS OF PIPELINE DRUGS IN ALZHEIMER’S DISEASE
- Table 6: KEY MILESTONES IN ALZHEIMER’S DISEASE THERAPEUTICS MARKET
- Table 7: KEY DEALS & COLLABORATIONS IN ALZHEIMER’S DISEASE THERAPEUTICS MARKET
- Table 8: KEY INACTIVE/DISCONTINUED PRODUCTS IN ALZHEIMER’S DISEASE THERAPEUTICS MARKET
CHAPTER – 1: ALZHEIMER’S DISEASE OVERVIEW
- Alzheimer’s Disease – An Overview
CHAPTER – 2: ALZHEIMER’S DISEASE EPIDEMIOLOGY & OVERVIEW
- 8MM: Historic & Projected Volume of Incidence & Prevalence of Alzheimer’s Disease
- 8MM: Comparative Analysis of Incidence & Prevalence of Alzheimer’s Disease
- 8MM: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Disease type
- 8MM: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Severity type
- 8MM: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Age Group
- 8MM: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Gender type
- 8MM: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Disease type
- 8MM: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Severity type
- 8MM: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Age Group
- 8MM: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Gender type
- US: Historic & Projected Volume of Incidence & Prevalence of Alzheimer’s Disease
- US: Comparative Analysis of Incidence & Prevalence of Alzheimer’s Disease
- US: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Disease type
- US: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Severity type
- US: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Age Group
- US: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Gender type
- US: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Disease type
- US: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Severity type
- US: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Age Group
- US: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Gender type
- China: Historic & Projected Volume of Incidence & Prevalence of Alzheimer’s Disease
- China: Comparative Analysis of Incidence & Prevalence of Alzheimer’s Disease
- China: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Disease type
- China: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Severity type
- China: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Age Group
- China: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Gender type
- China: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Disease type
- China: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Severity type
- China: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Age Group
- China: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Gender type
- Japan: Historic & Projected Volume of Incidence & Prevalence of Alzheimer’s Disease
- Japan: Comparative Analysis of Incidence & Prevalence of Alzheimer’s Disease
- Japan: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Disease type
- Japan: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Severity type
- Japan: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Age Group
- Japan: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Gender type
- Japan: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Disease type
- Japan: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Severity type
- Japan: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Age Group
- Japan: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Gender type
- Germany: Historic & Projected Volume of Incidence & Prevalence of Alzheimer’s Disease
- Germany: Comparative Analysis of Incidence & Prevalence of Alzheimer’s Disease
- Germany: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Disease type
- Germany: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Severity type
- Germany: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Age Group
- Germany: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Gender type
- Germany: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Disease type
- Germany: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Severity type
- Germany: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Age Group
- Germany: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Gender type
- UK: Historic & Projected Volume of Incidence & Prevalence of Alzheimer’s Disease
- UK: Comparative Analysis of Incidence & Prevalence of Alzheimer’s Disease
- UK: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Disease type
- UK: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Severity type
- UK: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Age Group
- UK: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Gender type
- UK: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Disease type
- UK: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Severity type
- UK: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Age Group
- UK: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Gender type
- France: Historic & Projected Volume of Incidence & Prevalence of Alzheimer’s Disease
- France: Comparative Analysis of Incidence & Prevalence of Alzheimer’s Disease
- France: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Disease type
- France: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Severity type
- France: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Age Group
- France: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Gender type
- France: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Disease type
- France: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Severity type
- France: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Age Group
- France: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Gender type
- Italy: Historic & Projected Volume of Incidence & Prevalence of Alzheimer’s Disease
- Italy: Comparative Analysis of Incidence & Prevalence of Alzheimer’s Disease
- Italy: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Disease type
- Italy: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Severity type
- Italy: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Age Group
- Italy: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Gender type
- Italy: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Disease type
- Italy: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Severity type
- Italy: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Age Group
- Italy: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Gender type
- Spain: Historic & Projected Volume of Incidence & Prevalence of Alzheimer’s Disease
- Spain: Comparative Analysis of Incidence & Prevalence of Alzheimer’s Disease
- Spain: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Disease type
- Spain: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Severity type
- Spain: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Age Group
- Spain: Historic & Projected Volume of Incidence of Alzheimer’s Disease cases by Gender type
- Spain: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Disease type
- Spain: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Severity type
- Spain: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Age Group
- Spain: Historic & Projected Volume of Prevalence of Alzheimer’s Disease cases by Gender type
CHAPTER – 3: ALZHEIMER’S DISEASE MARKET SIZE & OVERVIEW
- 8MM: Historic & Projected Revenue of Alzheimer’s Disease
- 8MM: Historic & Projected Revenue of Alzheimer’s Disease Snapshot
- 8MM: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
- US: Historic & Projected Revenue of Alzheimer’s Disease
- US: Historic & Projected Revenue of Alzheimer’s Disease Snapshot
- US: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
- China: Historic & Projected Revenue of Alzheimer’s Disease
- China: Historic & Projected Revenue of Alzheimer’s Disease Snapshot
- China: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
- Germany: Historic & Projected Revenue of Alzheimer’s Disease
- Germany: Historic & Projected Revenue of Alzheimer’s Disease Snapshot
- Germany: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
- Japan: Historic & Projected Revenue of Alzheimer’s Disease
- Japan: Historic & Projected Revenue of Alzheimer’s Disease Snapshot
- Japan: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
- France: Historic & Projected Revenue of Alzheimer’s Disease
- France: Historic & Projected Revenue of Alzheimer’s Disease Snapshot
- France: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
- Italy: Historic & Projected Revenue of Alzheimer’s Disease
- Italy: Historic & Projected Revenue of Alzheimer’s Disease Snapshot
- Italy: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
- UK: Historic & Projected Revenue of Alzheimer’s Disease
- UK: Historic & Projected Revenue of Alzheimer’s Disease Snapshot
- UK: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
- Spain: Historic & Projected Revenue of Alzheimer’s Disease
- Spain: Historic & Projected Revenue of Alzheimer’s Disease Snapshot
- Spain: Historic & Projected Revenue Segmentation by Gender Type, Disease Type, Severity Type, Age Group & Drug Class
CHAPTER – 4: ALZHEIMER’S DISEASE MARKETED DRUGS OVERVIEW
- Alzheimer’s Disease Marketed Drugs – An Overview
- Alzheimer’s Disease Marketed Drugs – Summary
CHAPTER – 5: ALZHEIMER’S DISEASE PIPELINE DRUGS OVERVIEW
- Alzheimer’s Disease Pipeline Drugs – An Overview
- Alzheimer’s Disease Pipeline Drugs – Snapshot
- Alzheimer’s Disease Pipeline Drugs Overview & Snapshot – By Disease type
- Alzheimer’s Disease Pipeline Drugs Overview & Snapshot – By Development Phase
- Alzheimer’s Disease Pipeline Drugs Overview & Snapshot – By Route of Administration
- Alzheimer’s Disease Pipeline Drugs Overview & Snapshot – By Mechanism of Action
- Alzheimer’s Disease Pipeline Drugs Overview & Snapshot – By Molecule type
- Alzheimer’s Disease Pipeline Drugs Overview & Snapshot – By Geography type
CHAPTER – 6: ALZHEIMER’S DISEASE CLINICAL TRIALS OVERVIEW
- Alzheimer’s Disease Clinical Trials Overview Snapshot
- Alzheimer’s Disease Clinical Trials Overview – By Recruitment Status
- Alzheimer’s Disease Clinical Trials Overview – By Product type
- Alzheimer’s Disease Clinical Trials Overview – By Route of Administration
- Alzheimer’s Disease Clinical Trials Overview – By Molecule type
- Alzheimer’s Disease Clinical Trials Overview – By Geography type
CHAPTER – 7: ALZHEIMER’S DISEASE MARKET DYNAMICS
- Alzheimer’s Disease Therapeutics Market Drivers
- Alzheimer’s Disease Therapeutics Market Constraints
- Alzheimer’s Disease Therapeutics Market Trends
CHAPTER – 8: ALZHEIMER’S DISEASE COMPETITIVE LANDSCAPE
- Alzheimer’s Disease Competitive Landscape – Marketed Drugs
- Key Company Profiles
- Other Key Company Profiles
- Competitive Scenario of Alzheimer’s Disease therapeutics market
- Key Company Profile Snapshot
- Other Key Company Profile Snapshot
- Alzheimer’s Disease Competitive Landscape – Pipeline Drugs
- Key Emerging Company Profiles
- Other Key Emerging Company Profiles
- Key Company Profile Snapshots
CHAPTER – 9: ALZHEIMER’S DISEASE MISCELLANEOUS
- Key Tentative Drug Approvals Timeline
- Key Regulatory Designations
- Key Milestones
- Deals & Collaborations
- Inactive/Discontinued/Dormant Products
- Unmet needs/Strategic Recommendations
CHAPTER – 10: APPENDIX
- About Arizton
- Research Methodology
- List of Abbreviations
Select a license type that suits your business needs
Single User Licence
- Report accessible by one user only
- Free 10% or 3 days of customization
- Free post-sale service assistance
- Continuous support through email
5 User Licence
- Report accessible by 5 users within the organization
- Free 15% or 4.5 days of customization
- Continuous support through email and telephone
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
- Free Datasheet worth $1500
- Report accessible by the entire organization
- Free 20% or 6 days of customization
- Free post-sale service assistance
- Continuous support through email and telephone
- Direct access to lead analysts
- Free analyst hour
- Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
- Report accessible by 1 user only
- Free 15% or 32 hours of customization
- Free post-sale service assistance
- Direct access to lead analysts
Frequently Asked Questions
How big is the Alzheimer's disease therapeutics market?
What is the growth rate of the global Alzheimer's disease therapeutics market?
What are some significant trends in the Alzheimer's disease therapeutics market?
Who are the leading vendors operating in the global Alzheimer's disease therapeutics market?
Which region holds the most extensive global Alzheimer's disease therapeutics market share?
other RELATED Reports
Crohn’s Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis
Published : September 2022
Psoriatic Arthritis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027
Published : October 2022
Atopic Dermatitis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027
Published : November 2022
Hepatocellular Carcinoma Treatment Market Forecast- Epidemiology & Pipeline Analysis 2022-2027
Published : January 2023